Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05523440 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
A Phase 2 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT05523440 is a Phase 2 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 9 participants.
The verdict
NCT05523440, a Phase 2 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the proportion of tumor response to the combination treatment with niraparib and bevacizumab and see what effects (good and bad) this combination treatment has on patients with recurrent endometrial or ovarian cancer with ARID1A mutation.
Interventions
- DRUG Bevacizumab
- DRUG Niraparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2025-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05523440
The ClinicalTrials.gov registry entry for NCT05523440 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT05523440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05523440 about?
NCT05523440 is a clinical study titled "Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation". The purpose of this research study is to test the proportion of tumor response to the combination treatment with niraparib and bevacizumab and see what effects (good and bad) this combination treatment has on patients with recurrent endometrial or ovarian cancer with ARID1A mutation.
What is the current status of trial NCT05523440?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2023-02-15. Estimated completion is 2025-01-08.
What interventions are being tested in trial NCT05523440?
The interventions under investigation include: Bevacizumab (DRUG), Niraparib (DRUG).
Who is sponsoring clinical trial NCT05523440?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.